4-(5-formyl-furan-2-yl)-benzamide | 68502-16-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(5-formyl-furan-2-yl)-benzamide
• 英文别名: 4-(5-Formylfuran-2-yl)benzamide
• CAS: 68502-16-9
• 化学式: C₁₂H₉NO₃
• mdl: MFCD03925028
• 分子量: 215.208
• InChiKey: VOHIDORBPOTXTO-UHFFFAOYSA-N

物化性质

• 沸点：
  450.0±40.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  73.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-formyl-furan-2-yl)-benzamide 在 哌啶 、 吡啶 、 氯化亚砜 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 反应 6.0h， 生成 4-[5-[(E)-3-[3-benzoyl-4-[[2-(4-methylphenyl)acetyl]amino]anilino]-3-oxoprop-1-enyl]furan-2-yl]benzamide
  参考文献：
  名称：

  Structure–activity relationships of novel anti-malarial agents. Part 7: N-(3-Benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties

  摘要：

  In a previous report, we have provided evidence that novel anti-malarial compounds based on 2,5-diaminobenzophenone farnesyltransferase inhibitors might benefit from the presence of a polar moiety at the para position of the terminal phenyl of the arylfurylacryloyl partial structure. Here, we demonstrate that different moieties with hydrogen bond acceptor properties lead to equipotent or even improved anti-malarial activity in comparison to the nitro group described before. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00353-6
• 作为产物：
  描述：

  5-碘-2-呋喃甲醛 、 4-氨基甲酰苯硼酸 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 乙醇 、 水 、 甲苯 为溶剂， 生成 4-(5-formyl-furan-2-yl)-benzamide
  参考文献：
  名称：

  Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114508

文献信息

• Synthesis and Biological Evaluation of 2-Phenylimino-5((5-phenylfuran-2-yl)methylene)thiazolidin-4-ones as IKK2 Inhibitors
  作者：Hee Sook Kim、Min Jae Shin、Byungho Lee、Kwang-Seok Oh、Hyunah Choo、Ae Nim Pae、Eun Joo Roh、Ghilsoo Nam

  DOI：10.1002/bkcs.10528

  日期：2015.11

  compounds with inhibitory action against the IKK2 enzyme using in silico methods. Based on the virtual hit of compounds 1 and 2, a novel series of 2‐phenylimino‐5((5‐phenylfuran‐2‐yl)methylene)thiazolidin‐4‐one derivatives was designed, synthesized, and evaluated for IKK2 inhibitory activity. Among the synthesized derivatives, compounds 17f and 19f showed good IKK2 inhibitory potency, which have 4‐carboxaminophenyl

  为了寻找治疗炎症性疾病的新分子，我们使用计算机方法鉴定了几种具有抑制IKK2酶抑制作用的化合物。基于化合物1和2的虚拟命中，设计，合成并评估了一系列新的2-苯基亚氨基-5（（5-苯基呋喃-2-基）亚甲基）噻唑烷-4-酮衍生物，并对其IKK2抑制活性进行了评估。在合成衍生物中，化合物17f和19f表现出良好的IKK2抑制潜能，在2-呋喃环上具有4-羧氨基苯基，在核心结构的2-位具有苯基亚氨基部分上的甲氧基。最有效的化合物是2-（2,4-二甲氧基苯基）亚氨基-5（（（5（4-羧氨基苯基）呋喃-2-基）亚甲基）噻唑烷-1-4-1（19f，IC 50 = 0.94μM）两种虚拟命中化合物对IKK2的协同作用。我们还鉴定了对白介素（IL）-17，CCK-8和肿瘤坏死因子-α（TNF-α）具有抑制活性的化合物，它们是NF-κB依赖的促炎细胞因子介体。
• Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification
  作者：Yunxuan Li、Guanglei Nan、Xianxin Hou、Yechao Yan、Yajun Yang、Ying Yang、Ke Li、Zhiyan Xiao

  DOI：10.1016/j.ejmech.2023.115856

  日期：2023.12

  The immunoproteasome has emerged as a potential therapeutic target for idiopathic pulmonary fibrosis (IPF). We report herein our efforts to discover novel non-peptidic immunoproteasome inhibitors as potential treatment for IPF. A structure-based virtual screening was initially performed and the hit compound VS-7 with an IC50 of 9.437 μM against β5i was identified. Hit evolution based on the interaction

  免疫蛋白酶体已成为特发性肺纤维化（IPF）的潜在治疗靶点。我们在此报告我们努力发现新型非肽免疫蛋白酶体抑制剂作为 IPF 的潜在治疗方法。最初进行了基于结构的虚拟筛选，并鉴定了针对 β5i 的IC 50为 9.437 μM的命中化合物VS-7 。基于VS-7相互作用模式的命中进化继续进行，并 获得了具有良好亚基选择性特征的有效 β5i 抑制剂54 (IC 50 = 8.463 nM)。化合物54还对 TNF-α 和 IL-6 的释放、NF-κB 的转录活性以及 TGF-β1 诱导的成纤维细胞增殖、活化和胶原蛋白合成产生显着影响。值得注意的是，当在博莱霉素诱导的 IPF 小鼠模型中以 30 mg/kg 给药时，化合物54显示出与临床药物尼达尼布相当的抗纤维化作用。结果表明，选择性抑制免疫蛋白酶体可能是治疗IPF的有效方法。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Structure−Activity Relationships of Phenyl-Furanyl-Rhodanines as Inhibitors of RNA Polymerase with Antibacterial Activity on Biofilms
  作者：Philippe Villain-Guillot、Maxime Gualtieri、Lionel Bastide、Françoise Roquet、Jean Martinez、Muriel Amblard、Martine Pugniere、Jean-Paul Leonetti

  DOI：10.1021/jm0703183

  日期：2007.8.1

  The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the need for completely novel classes of antibacterial agents. Accordingly, recent advances in the study of prokaryotic transcription open new opportunities for such molecules. This paper reports the structure-activity relationships of a series of phenyl-furanyl-rhodanines (PFRs) as antibacterial inhibitors of RNA polymerase (RNAP). The molecules have been evaluated for their ability to inhibit transcription and affect growth of bacteria living in suspension or in a biofilm and for their propensity to interact with serum albumin, a critical parameter for antibacterial drug discovery. The most active of these molecules inhibit Escherichia coli RNAP transcription at concentrations of <= 10 mu M and have promising activities against various Gram-positive pathogens including Staphylococcus epidermidis biofilms, a major cause of nosocomial infection.
• Discovery of potent and selective rhodanine type IKKβ inhibitors by hit-to-lead strategy
  作者：Hyeseung Song、Yun Suk Lee、Eun Joo Roh、Jae Hong Seo、Kwang-Seok Oh、Byung Ho Lee、Hogyu Han、Kye Jung Shin

  DOI：10.1016/j.bmcl.2012.06.088

  日期：2012.9

  Regulation of NF-kappa B activation through the inhibition of IKK beta has been identified as a promising target for the treatment of inflammatory and autoimmune disease such as rheumatoid arthritis. In order to develop novel IKK beta inhibitors, we performed high throughput screening toward around 8000 library compounds, and identified a hit compound containing rhodanine moiety. We modified the structure of hit compound to obtain potent and selective IKK beta inhibitors. Throughout hit-to-lead studies, we have discovered optimized compounds which possess blocking effect toward NF-kappa B activation and TNF alpha production in cell as well as inhibition activity against IKK beta. Among them, compound 3q showed the potent inhibitory activity against IKK beta, and excellent selectivity over other kinases such as p38 alpha, p38 beta, JNK1, JNK2, and JNK3 as well as IKK alpha. (C) 2012 Elsevier Ltd. All rights reserved.